learn HMI-115
much-hyped research compound targeting prolactin receptor in scalp
Search
forLearn
5 / 801 resultslearn TDM-105795
learn HT-B
learn RH410
learn LHA™
Research
5 / 1000+ results
research Recent approaches of antibody therapeutics in androgenetic alopecia
Antibody treatments show promise for hair loss but need more research.
research Recent Advances in Drug Development for Hair Loss
New treatments for hair loss show promise with advanced therapies and better targeting.
research Retrospective evaluation of Penguin Cold Caps for chemotherapy-induced alopecia
Penguin Cold Caps help most patients keep at least half their hair during chemotherapy.
research MINOXIDIL: HOPE FOR THE BALD?
Minoxidil helps some bald men, but most lose hair again when stopping.
research A Novel Hope for Alopecia Totalis Patients: Case Report
Tofacitinib may effectively regrow hair in alopecia totalis patients.
Community Join
5 / 1000+ resultscommunity Hope Medicine HMI-115 got 28M$ investment
Hope Medicine received a $28M investment for HMI-115, a monoclonal antibody in phase II trials for treating androgenetic alopecia. Some users are skeptical about its effectiveness, while others find the investment and trial results encouraging.
community Hope Medicine HMI-115 Phase 1 Success in Australia! 14 hairs/cm2 increase in hair growth.
The conversation discusses a new hair growth treatment that showed a 14 hairs/cm2 increase in a trial, with mixed opinions on its effectiveness and potential cost. Some users are hopeful about combining it with existing treatments like oral minoxidil for better results.
community Hope Medicine's HMI-115 could be out in 2027 per Company Founder
Hope Medicine's HMI-115 is expected to be released in 2027, with phase 3 trials currently recruiting. Concerns include the safety of targeting prolactin and the potential cost of the treatment.
community Hope Medicine announces HMI-115 phase II clinical trial for androgenetic alopecia in China
Hope Medicine's announcement of the HMI-115 Phase II clinical trial for androgenetic alopecia in China; other related trials have been conducted or are ongoing in different countries, including Australia, US, and Europe. There is speculation that the product may be accepted across borders without additional testing.
community HMI-115 update: Chime Biologics and Hope Medicine Enter Manufacturing Agreement to Speed up the Launch of First-in-class Antibody Drug HMI-115 Targeting Endometriosis and Androgenic Alopecia
Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.